BioSpace News Archive

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will present new data from the Phase 2 allergen chamber clinical trial of reproxalap ophthalmic solution (0.25% and 0.5%) in allergic conjunctivitis. The data will be presented in

Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the presentation of new data on the company’s novel hematopoietic progenitor kinase 1 (HPK1) inhibitors at upcoming scientific conferences. At the 32 nd EORTC-NCI-AACR Symposium, from October 24-25, 2020, Nimbus will present new in vivo data, including target eng

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a new in vivo gene therapy development program for the treatment of mucopolysaccharidosis type II (MPS II), or Hunter syndrome.

Many chemicals that affect cellular nuclear receptors can disrupt the endocrine system, leading to reproductive dysfunction, diabetes, metabolic diseases, and cancer.

Partnership to Improve Health Equity, Reduce Health Disparities, and Improve Community Health Amid COVID-19 Pandemic

Neovasc, Inc. (NASDAQ, TSX: NVCN) today announced that it will report financial results for the quarter ended September 30, 2020 after the market close on November 5, 2020.

Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, reports it has published a video interview with Dr. Ayman A. Alian, MBChB,

Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announces it has entered into a strategic cooperation agreement (the “Agreement”) with Chengdu Meb Network Technology Co., Ltd. (“Meb”),

Analysis Group, a global leader in health economics and outcomes research (HEOR), announced the publication of a study addressing the question of when radium-223 should be given to patients with metastatic castration resistant prostate cancer (mCRPC).

Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, announces a novel breakthrough in orthopaedic additive manufacturing with their ability to incorporate locking technology in all of their Patient Specific Implants.